Savara Inc. Aktie
Savara Inc. Aktie
Was spricht für und gegen Savara Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Savara Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Savara Inc. | -3,03 % | -5,88 % | -6,73 % | 152,12 % | -2,80 % | 163,29 % | -56,36 % |
Gritstone Oncology Inc | -0,33 % | 8,07 % | -69,33 % | -65,20 % | -59,63 % | -90,01 % | - |
Avid Bioservices Inc | 0,70 % | 12,70 % | 10,94 % | -54,49 % | 16,39 % | -59,89 % | 67,81 % |
Pacira Pharmaceuticals | 0,83 % | -3,23 % | -8,40 % | -39,70 % | -19,46 % | -53,40 % | -31,39 % |
Kommentare
News
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On March 21
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending